BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

被引：0

作者：

Jeanette E. Eckel-Passow

Daniel J. Serie

John C. Cheville

Thai H. Ho

Payal Kapur

James Brugarolas

R. Houston Thompson

Bradley C. Leibovich

Eugene D. Kwon

Richard W. Joseph

Alexander S. Parker

机构：

[1] Mayo Clinic,Division of Biomedical Statistics and Informatics

[2] Mayo Clinic,Department of Health Sciences Research

[3] Mayo Clinic,Laboratory Medicine and Pathology

[4] Mayo Clinic,Division of Hematology and Medical Oncology

[5] University of Texas Southwestern Medical Center,Department of Pathology

[6] University of Texas Southwestern Medical Center,Kidney Cancer Program, Simmons Comprehensive Cancer Center

[7] University of Texas Southwestern Medical Center,Division of Hematology

[8] Mayo Clinic,Oncology

[9] Mayo Clinic,Department of Urology

来源：

BMC Urology | / 17卷

关键词：

Clonal; Prognostic; Immunohistochemistry;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma
Piva, Francesco
Giulietti, Matteo
Occhipinti, Giulia
Santoni, Matteo
Massari, Francesco
Sotte, Valeria
Iacovelli, Roberto
Burattini, Luciano
Santini, Daniele
Montironi, Rodolfo
Cascinu, Stefano
Principato, Giovanni
[J]. ONCOTARGET, 2015, 6 (31) : 32161 - 32168
[42] Immune microenvironment in clear cell type renal cell carcinoma with loss of PBRM1 protein expression
Miura, Yuji
Motoshima, Takanobu
Inoshita, Naoko
Okaneya, Toshikazu
Takano, Toshimi
Komohara, Yoshihiro
[J]. ANNALS OF ONCOLOGY, 2019, 30
[43] Prognostic role of PBRM1 marker expression in clear-cell renal-cell carcinoma
Zaridze, D. G.
Mazurenko, N. N.
Bezhanova, S. D.
Maksimovich, D. M.
Shangina, O., V
Draudin-Krylenko, V. A.
Mukeria, A. F.
Matveev, V. B.
[J]. ONKOUROLOGIYA, 2019, 15 (01): : 23 - 31
[44] Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma
He, Donghua
Ma, Tianyan
Yi, Ni
Zhang, Sijie
Ding, Guanxiong
[J]. BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, 2023, 40 (04) : 3901 - 3915
[45] BAP1 Loss Results in mTORC1 Activation in Clear Cell Renal Cell Carcinoma
Kapur, P.
Christie, A.
Pena-Llopis, S.
Margulis, V.
Lotan, Y.
Xie, X-J
Brugarolas, J.
[J]. MODERN PATHOLOGY, 2013, 26 : 223A - 223A
[46] Characterization of the tumor immune microenvironment between primary and paired asynchronous metastatic clear cell renal cell carcinoma
Cotta, B. H.
Nallandhighal, S.
Mehra, R.
Cieslik, M.
Farha, M. W.
Kasputis, A.
Morgan, T. M.
Salami, S. S.
[J]. EUROPEAN UROLOGY, 2022, 81 : S1645 - S1645
[47] BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma
Langbein, Lauren E.
El Hajjar, Rayan
He, Shen
Sementino, Eleonora
Zhong, Zhijiu
Jiang, Wei
Leiby, Benjamin E.
Li, Li
Uzzo, Robert G.
Testa, Joseph R.
Yang, Haifeng
[J]. CANCER LETTERS, 2022, 547
[48] PBRM1 loss defines distinct tumor phenotype associated with immunotherapy resistance in renal cell carcinoma
Liu, Xiande
Kong, Wen
Peterson, Christine
McGrail, Daniel
Anh Hoang
Zhang, Xuesong
Truong Lam
Pilie, Patrick
Zhu, Haifeng
Beckermann, Kathryn
Haake, Scott
Isgandrova, Sevinj
Martinez-Moczygemba, Margarita
Sahni, Nidhi
Rathmell, W. Kimryn
Jonasch, Eric
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[49] BAP1 Loss Results in mTORC1 Activation in Clear Cell Renal Cell Carcinoma
Kapur, P.
Christie, A.
Pena-Llopis, S.
Margulis, V.
Lotan, Y.
Xie, X-J
Brugarolas, J.
[J]. LABORATORY INVESTIGATION, 2013, 93 : 223A - 223A
[50] The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma
Kim, Ji-Yeon
Lee, Se-Hoon
Moon, Kyung Chul
Kwak, Cheol
Kim, Hyeon Hoe
Keam, Bhumsuk
Kim, Tae Min
Heo, Dae Seog
[J]. JOURNAL OF UROLOGY, 2015, 194 (04): : 1112 - 1119

← 1 2 3 4 5 →